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Abstract
Objective—Recent evidence suggests that antibiotic use, which alters the gut microbiome, is 
associated with an increased risk of colorectal cancer. However, the association between antibiotic 
use and risk of colorectal adenoma, the precursor for the majority of colorectal cancers, has not 
been investigated.
Design—We prospectively evaluated the association between antibiotic use at age 20–39 and 40–
59 (assessed in 2004) and recent antibiotic use (assessed in 2008) with risk of subsequent 
colorectal adenoma among 16,642 women aged ≥60 enrolled in the Nurses’ Health Study who 
underwent at least one colonoscopy through 2010. We used multivariate logistic regression to 
calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results—We documented 1,195 cases of adenoma. Increasing duration of antibiotic use at age 
20–39 (Ptrend=0.002) and 40–59 (Ptrend=0.001) was significantly associated with an increased risk 
of colorectal adenoma. Compared to non-users, women who used antibiotics for ≥2 months 
between age 20–39 had a multivariable OR of 1.36 (95% CI: 1.03–1.79). Women who used ≥2 
months of antibiotics between age 40–59 had a multivariable OR of 1.69 (95% CI: 1.24–2.31). 
The associations were similar for low-risk vs. high-risk adenomas (size ≥1 cm, or with 
tubulovillous/villous histology, or ≥3 detected lesions), but appeared modestly stronger for 
proximal compared with distal adenomas. In contrast, recent antibiotic use within the past 4 years 
was not associated with risk of adenoma (Ptrend=0.44).
Conclusions—Long-term antibiotic use in early to middle adulthood was associated with 
increased risk of colorectal adenoma.
Keywords
antibiotics; colorectal adenomas; colonic microflora
INTRODUCTION
In recent years, antibiotic use has increased dramatically in the U.S.1 Accumulating 
evidence suggests that exposure to antibiotics may be associated with risk for chronic 
illnesses such as inflammatory bowel disease,23 celiac disease,4 and obesity.56 It is 
hypothesized that the link between antibiotics and disease pathogenesis may be mediated by 
their effect on the taxonomic, genomic, and functional capacity of the gut microbiota.7–9 
Similarly, increasing data have supported a role for the gut microbiota in colorectal 
carcinogenesis.10–12 Thus, antibiotics and their effects on the gut microbiome may lead to 
the promotion of biological pathways that initiate or promote colorectal neoplasia.13–15
Limited studies from cancer registries and healthcare claims in Europe with short-term 
follow-up suggest an association between antibiotic exposure and colorectal cancer.16–18 
Although these data are intriguing, limitations of these studies influence their interpretation. 
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First, the associations of antibiotics with colorectal cancer, particularly with shorter term 
follow-up may be due to residual confounding or reverse causality. For example, antibiotics 
may be more likely to be prescribed for symptoms associated with colorectal cancer or 
conditions that predispose to cancer prior to a formal diagnosis. Second, the association of 
recent antibiotic exposure with a higher likelihood of colorectal cancer diagnosis may also 
be indicative of closer or more frequent medical surveillance among these antibiotic users. 
Third, prior studies were based on cohorts that had limited information on potential lifestyle 
factors influencing the risk of colorectal cancer or the use of antibiotics. Fourth, given that 
colorectal cancer is believed to typically develop over at least a decade, the short-term 
follow-up data compiled by these studies are unlikely to capture the role of antibiotics in the 
initiation of colorectal neoplasia. Finally, these studies are derived from prescription records, 
which may not reflect actual use of these agents.
To address these limitations, we examined the association of both past and recent antibiotic 
use with risk of colorectal adenoma, the precursor of the majority of colorectal cancers, 
among women enrolled in the Nurses’ Health Study (NHS), which has collected detailed 
information on antibiotic use and lifestyle risk factors for colorectal cancer and endoscopic 
screening practices since 2004 and prospectively documented cases of adenoma through 
2010. Because colorectal adenomas are largely asymptomatic and detected only during a 
colonoscopy, an association between antibiotic use and adenoma among a cohort of 
individuals uniformly undergoing colonoscopy would be less likely to be confounded by 
symptoms associated with colorectal cancer or differential exposure to medical care.
METHODS
Study population
The NHS is an ongoing prospective cohort study of 121,700 U.S. female nurses aged 30–55 
at enrollment in 1976. Participants have been mailed questionnaires every 2 years since 
baseline to collect data on demographics, lifestyle factors, medical history, and disease 
outcomes, and every 4 years to collect dietary data. In this analysis, we excluded participants 
with a diagnosis of cancer (except non-melanoma skin cancer), ulcerative colitis, or 
colorectal polyp before 2004. To reduce the potential for detection bias, we restricted the 
analysis to 16,642 women aged 60 and above in 2004 who reported their history of antibiotic 
use through age 59 via the 2004 questionnaire and subsequently reported having undergone 
at least one colonoscopy between 2004 and 2010 on biennial follow-up questionnaires. This 
study was approved by the institutional review board at the Brigham and Women’s Hospital.
Ascertainment of colorectal adenoma cases and controls
On each biennial questionnaire, we asked whether participants had undergone a 
colonoscopy; what the indications for these procedures were; whether colon or rectal polyps 
had been diagnosed in the past two years; and if they had, the date of diagnosis. When a 
diagnosis was reported, we obtained informed consent to acquire medical records and 
pathology reports. Investigators blinded to any exposure information reviewed all records 
and extracted data on histological type, anatomic location, size and number of the polyps. If 
more than one adenoma was diagnosed, the subject was classified according to the largest 
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and most advanced histologic adenoma. Adenomas in the cecum, ascending colon, hepatic 
flexure, transverse colon or splenic flexure were classified as proximal; adenomas in the 
descending or sigmoid colon were classified as distal; and adenomas in the rectum or 
rectosigmoid junction were classified as rectal. We also grouped adenoma cases according to 
their features and subsequent likelihood of developing future advanced neoplasia: high-risk, 
defined as at least one adenoma ≥1 cm in diameter, or with advanced histology 
(tubulovillous/villous histologic features or high-grade or severe dysplasia), or ≥3 adenomas 
regardless of histology or size vs. low-risk, which included all other adenomas,19 size (large: 
≥1cm vs. small: <1 cm), histology (tubulovillous/villous vs. tubular), and multiplicity (≥3 vs. 
<3). Cases and controls were separately defined in each two-year period: all newly 
diagnosed adenomas were considered as cases and all the participants who reported 
colonoscopy but without a diagnosis of adenoma were defined as controls.
Assessment of antibiotic use
In 2004, participants reported their total time using antibiotics (excluding skin creams, 
mouthwash or Isoniazid) for the time periods between age 20–39 and 40–59. The responses 
were recorded in 8 categories (ranging from none to 5+ years). In 2008, participants recalled 
their total amount of time of antibiotic use (excluding skin creams, mouthwash or Isoniazid) 
during the past 4 years in 7 categories (ranging from none to 3+ years). They also reported 
the most common reason that an antibiotic was used, including respiratory infection, urinary 
tract infection (UTI), acne/rosacea, chronic bronchitis, dental, and other reason.
Statistical analysis
We evaluated the association between antibiotic use at age 20–39 and 40–59 (assessed in 
2004) with risk of colorectal adenoma among women who reported a colonoscopy between 
2004 and 2010 as the main analyses. The minimum detectable OR was 1.45 when 
comparing individuals who used antibiotics for 2 mo+ at age 20–39 to non-users, and 1.52 
for individuals who used antibiotics for 2 mo+ compared to non-users at age 40–59. We also 
examined exposure to antibiotics over the preceding 4 years (assessed in 2008) and risk of 
colorectal adenoma among women who had a colonoscopy between 2008–2010. In 
secondary analyses, we investigated the association between antibiotic exposure during each 
time period and risk of high vs. low-risk adenoma, as well as according to anatomic location, 
size, histological type, and number of adenomas. As an exploratory analysis, we examined 
the association between the most common reason for antibiotic use (assessed in 2008) and 
risk of colorectal adenoma among women who had a colonoscopy between 2008–2010.
To account for the possibility that a single individual may have undergone multiple 
endoscopies between 2004 and 2010 and to handle time-varying exposure and covariates 
efficiently, we used an Andersen-Gill data structure with a new record for each 2-year 
follow-up period during which a participant underwent a colonoscopy. Exposure and 
covariates were set to their values at the time that the questionnaire was returned. Once a 
participant was diagnosed with adenoma, she was censored in all later follow-up cycles. Age 
and multivariable-adjusted logistic regressions for clustered data (PROC GENMOD) were 
used to account for repeated observations (i.e. multiple endoscopies) and to calculate odds 
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ratios (ORs) approximating relative risks. Tests for trend were conducted using the median 
of the duration of antibiotic therapy as a continuous variable.
In age-adjusted models, we controlled for age in 5-year intervals, time period of 
colonoscopy (in 2-year intervals); number of endoscopies (continuous); time in years since 
the most recent endoscopy (continuous); and reason for the current colonoscopy(screening/
symptoms/missing). In the multivariable models, we additionally adjusted for the following 
potential confounders (cumulatively updated when applicable): history of colorectal cancer 
in a first degree relative (yes/no); personal history of diabetes (yes/no); use of menopausal 
hormone therapy (MHT) (never/past/current); body mass index (kg/m2 in quintiles); height 
(continuous); regular aspirin use (yes/no); current use of multivitamin (yes/no); physical 
activity (metabolic equivalent task [MET]-hrs/wk in quintiles); smoking (pack-years in 
categories: never smoker, 1–4.9, 5–19.9, 20–39.9, 40+); alcohol intake (g/d in categories: 
<5, 5–9.9, 10–14.9, 15–29.9, 30+); total calories (kcal/d in quintiles); folate intake (μg/d in 
quintiles); calcium intake (mg/d in quintiles); red and processed meat intake (servings/d in 
quintiles). To control for potential confounding by multiple dietary factors, we adjusted for 
Alternate Healthy Eating Index (AHEI)-2010 (in quintiles),20 which features greater 
consumption of vegetables (excluding potatoes), fruits (excluding juices); whole grains; 
nuts, legumes and vegetable protein, long chain omega-3 fatty acids, polyunsaturated fatty 
acids; and a lower consumption of sugar-sweetened beverages, red/processed meat, sodium, 
trans fat, and moderate alcohol consumption. Adherence to the AHEI-2010 has been 
associated with reduced risk of cardiovascular disease, diabetes and cancer in our cohorts.21 
Because alcohol was included as a separate term in our model, we used a modified 
AHEI-2010 without alcohol consumption. All the analyses were performed using SAS v 9.4 
(SAS Institute, Cary, NC). All the statistical tests were two-sided and P values less than 0.05 
were considered statistically significant.
RESULTS
We documented 1,195 newly diagnosed adenomas among 16,642 women aged ≥60 who had 
at least one colonoscopy between 2004 and 2010 and reported information on antibiotic use. 
We calculated the distribution of potential risk factors for adenomas according to duration of 
antibiotic use during age 20–39 (Table 1). Women who used antibiotics for longer duration 
were generally similar to women who did not have any antibiotic treatment in terms of 
family history of colorectal cancer, personal disease/screening history and lifestyle factors, 
but were more likely to regularly use menopausal hormone therapy and aspirin and undergo 
colonoscopy for symptoms (e.g. abdominal pain, diarrhea, constipation) rather than routine 
screening.
An increasing total exposure to antibiotics at age 20–39 was significantly associated with a 
higher risk of colorectal adenoma. Compared to non-users, women who used antibiotics for 
≥2 months during age 20–39 had a multivariable OR for adenoma of 1.36 (95% CI, 1.03–
1.79) (Ptrend=0.002) (Table 2). The associations were similar for high-risk (size ≥1cm, or 
with tubulovillous/villous histology, or ≥3) compared with low-risk adenomas (Table 2 and 
Supplemental Table 1). In contrast, a somewhat stronger association was observed for 
adenomas located in the proximal compared to distal colon (Table 2).
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Similarly, antibiotic use during age 40–59 was associated with an increased risk of colorectal 
adenoma. Women who used ≥2 months of antibiotics during age 40–59 had a multivariable 
OR for adenoma of 1.69 (95% CI, 1.24–2.31) (Table 3 and Supplemental Table 2). The 
associations were similar for low-risk vs. high-risk adenomas (Table 3). Longer duration of 
antibiotic treatment appeared to be more strongly associated with proximal adenomas (Table 
3). Compared to non-users of antibiotics between age 20–39 and 40–59, women who used 
antibiotics for more than 15 days between both age 20–39 and more than 15 days between 
age 40–59 had a multivariable OR for adenoma of 1.73 (95% CI,1.19–2.51) (Supplemental 
Table 3).
In contrast, recent antibiotic use did not appear associated with risk of colorectal adenoma. 
Among women who had a colonoscopy between 2008 and 2010, antibiotic use in the past 4 
years was not associated with risk of adenoma (Ptrend=0.44) (Table 4). In addition, none of 
the indications for antibiotic use appeared to be significantly associated with risk of 
adenoma (Supplemental Table 4).
DISCUSSION
In this prospective analysis nested in a large cohort of women with well-characterized risk 
factors for colorectal neoplasia, exposure to antibiotics earlier in life (age 20–39 and 40–59) 
was significantly associated with an increased risk for colorectal adenoma after age 60. In 
contrast, more recent antibiotic use (within 4 years) was not associated with risk. To the best 
of our knowledge, this study is the first to link duration of antibiotic use, in a dose-
dependent fashion, to colorectal adenoma, the primary precursor of colorectal cancer.
Our results are supported by prior studies of antibiotics and risk of colorectal cancer. A 
cohort study in Finland found that compared to people with ≤1 prescription for antibiotics, 
people who had ≥6 prescriptions had a 15% increased risk of developing colon cancer 
during up to 9 years of follow-up.16 With a median follow-up of 6.2 years, a nested case-
control study in The Health Improvement Network (THIN) of the UK suggested that the first 
antibiotic exposure to penicillins, cephalosporins, TMP-SMX (Trimethoprim/
sulfamethoxazole), and nitroimidazoles was associated with an increased risk of colorectal 
cancer within 1–5 years. Although no association was noted for exposure to most antibiotics 
>5 years before diagnosis, initial use of penicillin >10 years prior to diagnosis was 
associated with an increased risk of colorectal cancer, suggesting a possible role in the 
earliest stage of initiation of colorectal neoplasia.17 A nested case-control study from the 
Netherlands also observed an increased risk of colorectal cancer associated with antibiotic 
use within 1–6 years before diagnosis.18 Finally, in a nested case-control study among 
diabetic patients in Taiwan, prescriptions for antibiotics with anaerobic coverage, but not 
anti-aerobic coverage, were linked to an elevated risk of colorectal cancer.22 Our study 
significantly extends the findings of these prior studies by demonstrating an association of 
antibiotics with colorectal adenoma and its location, providing additional support that the 
association of antibiotics with colorectal cancer may be causal.
The proposed link between exposure to antibiotics and development of colorectal neoplasia 
is biologically plausible. Antibiotics shift the gut microbiota to temporally quasi-stable or 
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alternative stable states.2324 Although it is unknown what factors influence either the 
recovery of gut microbiota to its native state or the development of alternative states after 
antibiotic exposure,25 this dysbiosis is generally marked by a loss of diversity, alternations in 
the abundance of specific taxa, shifts in metabolic capacity, and reduced resistance to 
colonization by invading pathogens.1426–28 Studies have observed depletion of the phyla 
Bacteroidetes, Firmicutes (Clostridia), and Proteobacteria (Enterobacteriaceae), but 
enrichment in Fusobacteria in patients with colorectal cancer.2930 The interactions of these 
dysbiotic microbiota with mucosal immune and epithelial cells may be critical in the 
initiation and/or promotion of colorectal carcinogenesis.10121431 The higher bacterial 
concentration and fermentation in the proximal colon32 may also explain the observed 
stronger link between antibiotics and proximal adenomas. Finally, it is worth noting that 
pathogens that necessitate the use of antibiotics may induce inflammation, a known risk for 
colorectal cancer.33 Thus, it is possible that the observed link between antibiotics and 
adenoma may be mediated by inflammation.
Strengths of our study include detailed assessment of antibiotic use in early and middle 
adulthood, as well as recent antibiotic exposure and prospective follow-up to examine the 
influence of long-term and short-term impact of antibiotics on colorectal carcinogenesis with 
minimal recall bias. We were also able to control for a range of important potential 
confounders, (e.g. dietary factors and physical activity), which were not included in previous 
analyses. In addition, although we have limited power to evaluate the association with 
adenomas defined by their anatomic location, it is worth noting that earlier life antibiotic 
exposure was more strongly associated with proximal adenomas, the subtype of adenoma 
that is less likely to be detected by screening colonoscopy.34 Finally, our data, collected from 
health professionals, are more likely to reflect actual use of these agents in contrast to prior 
studies that relied on prescription information.
Our study also had several limitations. First, we did not access information on spectrum and 
route of administration of antibiotics. As a result, we are not able to investigate the 
differential effects of distinct antimicrobial classes. Nonetheless, if the effect of antibiotics 
on cancer is specific to only specific subtypes of antibiotics, our findings would be expected 
to be diluted. Moreover, it has been hypothesized that the influence of antibiotics on 
carcinogenesis is not dependent on the antimicrobial spectrum of the agent since the gut 
microbial ecosystem is co-dependent; thus perturbations specific to certain strains would be 
expected to have a broader impact on overall gut microbial composition and function.1428 
Nonetheless, the long-term impact of recently more commonly used antibiotics (e.g. 
rifaximin) should be examined in future studies. Second, measurement errors associated 
with recall of exposure to antibiotics during early life periods may be present. However, they 
would be expected to be non-differential to adenoma diagnosis. Third, as an observational 
study, the potential for residual confounding cannot be ruled out. Fourth, because age of 
exposure is closely correlated with duration of exposure and time since last exposure, we 
were unable to disentangle these factors to examine the independent association of these 
variables on risk. The specific timing of antibiotic exposure relative to development of 
adenoma is unclear since the diagnosis of adenoma was dependent on undergoing 
colonoscopy. Thus, some adenomas may have been prevalent at the time of antibiotic 
exposure but not yet detected. However, we observed an association of antibiotic use several 
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decades before colonoscopy, minimizing this likelihood. Finally, the generalizability of our 
data to other populations, particularly men and other racial or ethnic groups, is not known. 
Thus, further research is needed to confirm these findings.
In conclusion, early to middle adulthood antibiotic use was associated with increased risk of 
colorectal adenoma, especially in the proximal colon. These data provide additional support 
for the association of antibiotics with colorectal cancer and the potential mediating role of 
the gut microbiome in carcinogenesis. Additional studies investigating the impact of 
antibiotic exposure with gut microbial composition and function, particularly in relation to 
the mechanisms underlying colorectal carcinogenesis, are warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Summary Box
1. What is already known about this subject: 3–4 bullet points
• Increasing data have supported a role for the gut microbiota in colorectal 
carcinogenesis.
• Limited studies from cancer registries and healthcare claims with short-term 
follow-up suggest an association between antibiotic exposure and colorectal 
cancer.
• The association between antibiotic use and risk of colorectal adenoma, the 
precursor for the majority of colorectal cancers, has not been investigated.
2. What are the new findings: 3–4 bullet points
• Exposure to antibiotics earlier in life (age 20–39 and 40–59) was significantly 
associated with an increased risk for colorectal adenoma after age 60.
• More recent antibiotic use (within 4 years) was not associated with risk of 
colorectal adenoma.
• These data provide additional support for the association of antibiotics with 
colorectal cancer and the potential mediating role of the gut microbiome in 
carcinogenesis.
3. How might it impact on clinical practice in the foreseeable future?
• The findings, if confirmed by other studies, suggest the potential need to limit 
the use of antibiotics and sources of inflammation that may drive tumor 
formation.
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Supplemental Table 1. Antibiotic use at age 20-39 and risk of colorectal adenoma by size, histology and multiplicity, NHS 2004-2010  
  Antibiotic use at age 20-39 
Ptrend 
  None 1-14 d 15 d-2 mo 2 mo+ 
Large           
  No. of cases (n=305) 32 176 72 25   
  Age-adjusted* OR (95% CI) 1(referent) 1.34(0.91-1.97) 1.52(0.98-2.33) 1.46(0.85-2.51) 0.22 
  Multivariable† OR (95% CI) 1(referent) 1.32(0.89-1.95) 1.57(1.02-2.43) 1.56(0.90-2.71) 0.10 
Small           
  No. of cases (n=884) 104 477 223 80   
  Age-adjusted* OR (95% CI) 1(referent) 1.12(0.90-1.40) 1.43(1.12-1.83) 1.40(1.03-1.91) 0.001 
  Multivariable† OR (95% CI) 1(referent) 1.12(0.89-1.40) 1.43(1.11-1.83) 1.37(1.00-1.88) 0.003 
Villous           
  No. of cases (n=177) 22 105 34 16   
  Age-adjusted* OR (95% CI) 1(referent) 1.27(0.78-2.05) 1.17(0.66-2.09) 1.57(0.80-3.10) 0.43 
  Multivariable† OR (95% CI) 1(referent) 1.23(0.76-1.99) 1.15(0.65-2.03) 1.51(0.75-3.05) 0.48 
Tubular           
  No. of cases (n=836) 101 440 222 73   
  Age-adjusted* OR (95% CI) 1(referent) 1.05(0.84-1.32) 1.45(1.13-1.86) 1.30(0.95-1.78) 0.001 
  Multivariable† OR (95% CI) 1(referent) 1.05(0.83-1.32) 1.44(1.12-1.86) 1.31(0.95-1.80) 0.002 
≥3 Adenomas           
  No. of cases (n=144) 15 85 33 11   
  Age-adjusted* OR (95% CI) 1(referent) 1.51(0.87-2.63) 1.69(0.90-3.18) 1.64(0.75-3.61) 0.33 
  Multivariable† OR (95% CI) 1(referent) 1.57(0.88-2.80) 1.82(0.95-3.49) 1.82(0.81-4.11) 0.22 
1-2 Adenoma(s) 
     
  No. of cases (n=1051) 126 568 263 94 
 
  Age-adjusted* OR (95% CI) 1(referent) 1.08(0.88-1.33) 1.37(1.09-1.72) 1.33(1.00-1.77) 0.002 
  Multivariable† OR (95% CI) 1(referent) 1.07(0.87-1.32) 1.37(1.09-1.72) 1.31(0.98-1.75) 0.003 
*Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current 
colonoscopy. 
†Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass 
index, height, regular use of aspirin, current use of multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed 
meat intake, and Alternate Healthy Eating Index (AHEI) 2010.  
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Supplemental Table 2. Antibiotic use at age 40-59 and risk of colorectal adenoma by size, histology and multiplicity, NHS 2004-2010  
  Antibiotic use at age 40-59 
Ptrend 
  None 1-14 d 15 d-2 mo 2 mo+ 
Large           
  No. of cases (n=305) 18 168 89 30   
  Age-adjusted* OR (95% CI) 1(referent) 1.32(0.81-2.15) 1.42(0.85-2.38) 1.46(0.81-2.64) 0.34 
  Multivariable† OR (95% CI) 1(referent) 1.32(0.79-2.18) 1.46(0.86-2.47) 1.48(0.80-2.72) 0.29 
Small           
  No. of cases (n=884) 47 469 263 105   
  Age-adjusted* OR (95% CI) 1(referent) 1.39(1.02-1.88) 1.58(1.15-2.18) 1.89(1.32-2.70) <0.001 
  Multivariable† OR (95% CI) 1(referent) 1.35(0.99-1.83) 1.53(1.11-2.10) 1.81(1.26-2.60) 0.001 
Villous           
  No. of cases (n=177) 12 97 47 21   
  Age-adjusted* OR (95% CI) 1(referent) 1.20(0.65-2.20) 1.22(0.64-2.34) 1.70(0.82-3.50) 0.17 
  Multivariable† OR (95% CI) 1(referent) 1.15(0.62-2.12) 1.15(0.60-2.21) 1.59(0.76-3.33) 0.24 
Tubular           
  No. of cases (n=836) 45 442 257 92   
  Age-adjusted* OR (95% CI) 1(referent) 1.36(0.99-1.86) 1.60(1.15-2.21) 1.71(1.18-2.47) 0.003 
  Multivariable† OR (95% CI) 1(referent) 1.36(0.99-1.87) 1.60(1.15-2.23) 1.68(1.16-2.45) 0.01 
≥3 Adenomas           
  No. of cases (n=144) 7 85 38 14   
  Age-adjusted* OR (95% CI) 1(referent) 1.79(0.82-3.92) 1.71(0.75-3.90) 1.96(0.77-4.98) 0.57 
  Multivariable† OR (95% CI) 1(referent) 1.67(0.76-3.66) 1.66(0.73-3.77) 1.76(0.69-4.55) 0.64 
1-2 Adenoma(s)           
  No. of cases (n=1051) 59 552 319 121 
 
  Age-adjusted* OR (95% CI) 1(referent) 1.29(0.98-1.71) 1.51(1.13-2.01) 1.71(1.24-2.37) <0.001 
  Multivariable† OR (95% CI) 1(referent) 1.28(0.97-1.69) 1.49(1.11-1.99) 1.69(1.21-2.34) <0.001 
*Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current 
colonoscopy. 
†Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass 
index, height, regular use of aspirin, current use of multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed 
meat intake, and Alternate Healthy Eating Index (AHEI) 2010.  
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Supplemental Table 3. Joint analysis of antibiotic use at age 20-39 and 40-59 and risk of colorectal adenoma*, NHS 2004-2010 
Age 20-39 Age 40-59 
None 1-14 d 15 d+ 
None 34 88 20 
 1(referent) 1.29(0.86-1.95) 1.26(0.70-2.28) 
1-14 d 28 489 151 
 1.06(0.63-1.78) 1.37(0.95-1.97) 1.47(1.00-2.18) 
15 d+ 4 72 327 
 1.01(0.34-2.94) 1.56(1.02-2.40) 1.73(1.19-2.51) 
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Supplemental Table 4. Reason for antibiotic use and risk of colorectal 
adenoma, NHS 2008-2010 
    No. of cases/non-cases OR (95% CI) 
Respiratory infection 52/1724 1(referent) 
UTI 30/629 1.50(0.94-2.39) 
Acne/Rosacea 1/55 0.50(0.07-3.80) 
Chronic Bronchitis  2/96 0.71(0.17-3.04) 
Dental 27/842 1.10(0.67-1.81) 
Other Reason 22/795 0.87(0.51-1.48) 
*Adjusted for the same set of covariates as in Table 2. 
 
 
